Robotic Surgery For Endometrial Cancer

Robotic Surgery For Endometrial Cancer

The Robotic Surgery for Endometrial Cancer market was valued at USD 128.7 million in 2022. Robotic surgery involves the use of robotic systems to perform surgical procedures with enhanced precision and control. Endometrial cancer is the most common type of gynecologic cancer, and surgical treatment is often a primary approach for early-stage cases. Robotic surgery has gained popularity in the field of gynecologic oncology due to its advantages over traditional open surgery or laparoscopic techniques. The increasing prevalence of endometrial cancer and the increasing adoption of advanced technology in healthcare facilities are the major reasons contributing to the market growth of robotic surgery for endometrial cancer. For instance, as per World Cancer Research Fund International, there were more than 417,000 new cases of endometrial cancer in 2020.

Robotic Surgery for Endometrial Cancer Market is expected to grow at a strong CAGR of 15.8% during the forecast period (2023-2030) owing to the rising geriatric population and cases of cancer. For instance, according to Globocan 2020, 9439 Cervix uteri cases were registered in Mexico in 2020. Furthermore, the five-year prevalence of disease was 25,026 in 2020 in females of all ages.

• Based on components, the market is segmented into robotic surgery systems and maintenance services. Robotic surgery systems dominated the market in 2022. Robotic surgery is relatively a newer approach in the medical industry and the demand for robotic systems is high which is the responsible factor for the large share of robotic systems in endometrial cancer surgeries.
• Based on surgery type, the market is segmented into cryosurgery, laser surgery, hysterectomy, and others. The hysterectomy category is expected to witness the fastest growth during the forecast period. Hysterectomy is a surgical procedure that involves the removal of the uterus. A hysterectomy is a common that is performed by robotic systems in case of uterine cancer. The hysterectomy is a less complex surgery that can be performed by robotic systems easily which is an important reason for the largest share of the segment.
• On the basis of end-users, the market is categorized into hospitals & clinics, research centers, and others. Among these, the hospitals & clinics category held a significant share of the market in 2022. This is mainly due to the rising number of cancer cases, along with the increasing hospitalization are the major factors responsible for the segmental growth of the hospitals.
• For a better understanding of the market adoption of the industry, the market is analyzed based on its worldwide presence in the countries such as North America (U.S., Canada, and the Rest of North America), Europe (Germany, UK, France, Italy, Spain, Rest of Europe), Asia-Pacific (China, Japan, India, South Korea, Australia, and Rest of Asia-Pacific), Rest of World. North America held dominating share of the Robotic Surgery for Endometrial Cancer market in 2022. The market for robotic surgery for endometrial cancer is witnessing growth in the region due to the presence of developed countries such as the U.S. and Canada in the region. The frequent product launches and the adoption of newer technologies in the region is the major attributing factor for the growth of robotic surgery for endometrial cancer in the region. For instance, in March 2023, University Hospital launched single-port robotic surgery for the treatment of urological cancers and other conditions. Further, the region is known for its healthcare infrastructure is also the major reason for the proliferation of advanced technology in cancer treatment which is also an important factor responsible for the majority share of North America in robotic surgery for endometrial cancer.
• Some of the major players operating in the market include Intuitive Surgical; Stryker; Accuray Incorporated; NuVasive, Inc; Smith+Nephew; Asensus Surgical US, Inc.; Medtronic; Auris Health, Inc.; Siemens Healthcare GmbH; and Renishaw plc..